NICHD-2012-STA01 was a multiple center, open label, multiple-dose pharmacokinetic study. The primary objective of this study was to determine the pharmacokinetics (PK) of rifampin, ticarcillin-clavula
Timing and findings of physical exam, including system review and conditions or abnormalities Study Description An open-label, multiple-dose study to determine the safety, tolerability, and pharmacoki
HER2-positive cancer is a cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). HER2 promotes the growth of certain cancer cells. This study will test an e
